Pyrotech Therapeutics raises 300M CNY to develop pyroptosis-based drugs

What's the deal? Pyrotech Therapeutics, a Chinese biotech developing small-molecule drugs for inflammation and cancer, has raised 300 million CNY (about $44 million) in a Series B round. Shanghai Guotou Xiandao led the round, with Zhongguancun Science City Fund and Minjin Investment joining.

Who else backed it? Existing investors added capital, including Guoxin FundDealroom has a profile for this one. Try Dealroom →, Beijing Pharmaceutical and Health Fund, Qinglan CapitalDealroom has a profile for this one. Try Dealroom →, Frees FundDealroom has a profile for this one. Try Dealroom →, Qisheng CapitalDealroom has a profile for this one. Try Dealroom →, Chang Development Group, and Zhongfa Lingchuang.

What's the endgame? The company focuses on pyroptosis, a form of programmed cell death, as a route to novel treatments. It aims to develop small-molecule drugs with new mechanisms of action to address unmet clinical needs in inflammation and oncology.

The signal: Continued backing from state-linked and health-focused funds points to sustained investor appetite for mechanism-driven biotech in China, particularly platforms targeting inflammation and tumours.

Read more: ITjuzi

Image credit: umseas